Estimation of clinical trial success rates and related parameters
with Chi Heem Wong, Kien Wei Siah, Biostatistics (2018) 00, 00, pp. 1–14
What Post-Crisis Changes Does the Economics Discipline Need?: Beware of Theory Envy!
What’s the Use of Economics?: Teaching the Dismal Science After the Crisis, London Publishing Partnership.
The FTSE StableRisk Indices
with Jeremiah Chafkin and Robert Sinnott, Journal of Index Investing 2(2011), 12–35.
Managing real-time risks and returns: The Thomson Reuters NewsScope Event Indices
with Alexander D. Healy, The Handbook of News Analytics in Finance
Just how good an investment is the biopharmaceutical sector?
with Richard T Thakor, Nicholas Anaya, Yuwei Zhang, Christian Vilanilam, Kien Wei Siah, Chi Heem Wong, Nature Biotechnology
Do Stock Prices Follow Random Walks?
with A. Craig MacKinlay, Financial Times
Re-inventing drug development: A case study of the I-SPY 2 breast cancer clinical trials program
with Sonya Das, Contemporary Clinical Trials 62 (2017) 168–174
The Growth of Relative Wealth and the Kelly Criterion
with H. Allen Orr and Ruixun Zhang, Journal of Bioeconomics April 2018, Volume 20, Issue 1, pp 49–67
Buying Cures vs. Renting Health: Financing Healthcare via Consumer Loans
with Vahid Montazerhodjat and David Weinstock, Science Translational Medicine 8(2016), 327ps6
Dealing with Femtorisks in International Relations
with Aaron Benjamin Frank, Margaret Goud Collins, Simon A. Levin, Andrew W. Lo, Joshua Ramo, Ulf Dieckmann, Victor Kremenyukf, Arkady Kryazhimskiy, JoAnne Linnerooth-Bayer, Ben Ramalingam, J. Stapleton Roy, Donald G. Saari, Stefan Thurner, and Detlof von Winterfeldt, Proceedings of the National Academy of Sciences 111(2014), 17356–17362.